Approval · Notice of Compliance 30412 · 2023
FERRIPROX: Notice of Compliance 30412
Issued March 29, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30412
- Date
- March 29, 2023
- Company
- Chiesi Canada Corp.Woodbridge, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New dosage form and to convert the Product Monograph to the Master Template.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| FERRIPROX | Not yet assigned | — |
| FERRIPROX MR | 02536579 | Marketed |
Medicinal ingredients
- DEFERIPRONE 500 MG per TAB
- DEFERIPRONE 1,000 MG per TAB
- DEFERIPRONE 100 MG per ML